Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 5/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 5/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecane SCHEMBL30193423 | 0.93 | EPHX1 (0.67) | EPHX1FAAHCES1CES2 | |
| Nonane SCHEMBL30193525 | 0.93 | EPHX1 (0.67) | EPHX1FAAHCES1CES2 | |
| Butane SCHEMBL29598328 | 0.90 | EPHX1 (0.50) | EPHX1CA1CA2CA7PTPN11 | |
| Butane SCHEMBL30418608 | 0.90 | EPHX1 (0.50) | EPHX1CA1CA2CA7PTPN11 | |
| SCHEMBL29615765 | 0.85 | EPHX1 (0.48) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL29489328 | 0.85 | EPHX1 (0.48) | EPHX1CA1CA2CA12CA7 | |
| Tetrabuthylammonium SCHEMBL31550869 | 0.85 | EPHX1 (0.53) | EPHX1FAAHTSHRSMN1; SMN2 | |
| SCHEMBL21331448 | 0.83 | EPHX1 (0.47) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL12386312 | 0.82 | EPHX1 (0.50) | EPHX1CA1CA2CA12CA7 | |
| SCHEMBL303834 | 0.82 | EPHX1 (0.55) | EPHX1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301317-A1 | METHOD FOR SEPARATING AND QUANTIFYING SATURATED AND UNSATURATED DIALKYL KETONES | FUJI OIL HOLDINGS INC. (JP) | 2024-09-12 | — | — | US | disclosed |
| US-12000809-B2 | Zwitterionic compounds as gas chromatographic column stationary phases | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4368690-A1 | METHOD FOR SEPARATING AND QUANTIFYING SATURATED AND UNSATURATED DIALKYL KETONES | Fuji Oil Holdings Inc. (JP) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023282169-A1 | METHOD FOR SEPARATING AND QUANTIFYING SATURATED AND UNSATURATED DIALKYL KETONES | 不二製油グループ本社株式会社 | 2023-01-12 | — | — | WO | disclosed |
| US-20220268746-A1 | ZWITTERIONIC COMPOUNDS AS GAS CHROMATOGRAPHIC COLUMN STATIONARY PHASES | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11353435-B2 | Zwitterionic compounds as gas chromatographic column stationary phases | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220268746-A1 | ZWITTERIONIC COMPOUNDS AS GAS CHROMATOGRAPHIC COLUMN STATIONARY PHASES | GCG, ZW10, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EPHX1 2178/4885CA1 288/4885CA2 574/4885 |
| US-12000809-B2 | Zwitterionic compounds as gas chromatographic column stationary phases | GCG, ZW10, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EPHX1 2178/4885CA1 288/4885CA2 574/4885 |
| US-11353435-B2 | Zwitterionic compounds as gas chromatographic column stationary phases | GCG, ZW10, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EPHX1 2178/4885CA1 288/4885CA2 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.